A5103147657- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Biosimilars and Bioanalytical Methods
- Bone health and treatments
- Prostate Cancer Treatment and Research
- Medical Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Erythrocyte Function and Pathophysiology
- Lung Cancer Research Studies
- Cytokine Signaling Pathways and Interactions
- Erythropoietin and Anemia Treatment
- Blood disorders and treatments
- Microbial Metabolism and Applications
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Traditional Chinese Medicine Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Xuzhou Central Hospital
2012-2025
Xuzhou Medical College
2021
Southeast University
2012
PURPOSE We evaluated the efficacy and safety of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, for chemotherapy-induced anemia (CIA) in patients with nonmyeloid malignancies receiving multicycle treatments chemotherapy. PATIENTS AND METHODS In this open-label, noninferiority phase III study conducted at 44 sites China, 159 participants age ≥18 years CIA malignancy were randomly assigned (1:1) to oral roxadustat or subcutaneous recombinant human...
Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess equivalence LY01011 denosumab terms efficacy and safety. Eligible BM from solid tumors were randomized at 1:1 ratio receive 120 mg or subcutaneously every four weeks during 12-week double-blind period, then all enrolled continued until week 53. The primary endpoint natural logarithm change urinary N-terminal crosslinked...
Denosumab has been approved for the treatment of bone metastases from solid tumors. QL1206 is first denosumab biosimilar and needs to be compared with in a phase III trial. This trial aims compare efficacy, safety, pharmacokinetics between patients randomized, double-blind, was conducted 51 centers China. Patients aged 18–80 years, tumors metastases, an Eastern Cooperative Oncology Group performance status 0–2 were eligible. study divided into 13-week double-blind period, 40-week open-label...
9014 Background: This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced NSCLC. Methods: dose-escalation dose-expansion phase 1 trial recruited previously EGFR ex20ins mutant locally metastatic NSCLC T790M rare mutations. In phase, mutation were enrolled. YK-029A was given at doses 50, 100, 150, 200 250 mg/day (3+3 design). T790M,...
Abstract In the multicenter, dose-escalation and dose-expansion phase 1 clinical trial (NCT05767866), we evaluated safety tolerability of YK-029A in various EGFR mutated non-small-cell lung cancer (NSCLC). We have reported efficacy untreated NSCLC with ex20ins mutation[1]. This time report patients acquired T790M mutation after failure first or second generation tyrosine kinase inhibitors (TKIs). Method: recruited previously treated rare mutations. phase, were enrolled. was given at doses...
Data on composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell (LBCL) classical Hodgkin (cHL) are rare.We identified 25 cases with (CL), 116 developing LBCL as a second cancer after cHL (cHL-LBCL), 74 (LBCL-cHL) from the Surveillance, Epidemiology, End Results (SEER) 18 database. Comparisons of overall survival (OS) cause-specific (CSS) patients cHL-LBCL or their de novo counterparts were performed.The 5-year OS CL was 74.8 %. No significant difference in...
12126 Background: The study was to evaluate the equivalence of LY01011 reference product denosumab in terms reduction bone metabolism markers. Methods: Eligible patients were randomized at 1:1 ratio receive 120 mg injection or every four weeks subcutaneously. Following completion three doses a 12-week double-blind treatment period (DBTP), all enrolled would continue administration until week 53 follow-up period. primary end point natural logarithm change 13 from baseline urinary cross-linked...
Objective To study the effect of Kanglaite combined with comprehensive therapy on advanced non-small cell lung cancer.Methods Sixty-one patients cancer were randomly divided into treatment group ( n=31 ) and control n=30 ).Both groups given therapy.Treatment additionally treated intravenous injection 200 ml Kanglaite.Clinical efficacy,quality life,pain relief adverse reactions two observed.Results 1 Quality life was improved in 20 cases (64.5％ ),stabled 8 (25.8％),declined 3 9.7％ group,and...
2526 Background: This phase III study compared clinical efficacy, safety of the first biosimilar QL1206 with denosumab in solid tumor patients bone metastases. Methods: Patients aged 18-80 years, metastatic tumors and ECOG performance status 0-2 were randomly assigned 1:1 to receive subcutaneous or (120 mg Q4W, both) based on stratification factors (tumor types, previous skeletal-related event [SRE], current systemic anti-tumor therapy). The primary efficacy endpoint was percentage changes...